Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2001 Jun;60(6):566–572. doi: 10.1136/ard.60.6.566

Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area

J Hamilton 1, I McInnes 1, E Thomson 1, D Porter 1, J Hunter 1, R Madhok 1, H Capell 1
PMCID: PMC1753672  PMID: 11350844

Abstract

OBJECTIVE—To compare the risk-benefit ratio of intramuscular gold (gold sodium thiomalate (GST)) and methotrexate (MTX) in a population with rheumatoid arthritis (RA) from a deprived area.
METHODS—Patients with active RA were randomly assigned to open treatment with GST or MTX. Clinical and laboratory assessment was performed at 0, 12, 24, and 48 weeks. Results were analysed on an intention to treat basis.
RESULTS—141 patients were recruited—72 were randomly allocated to GST and 69 to MTX. There were no statistically significant differences found in either the clinical or demographic variables at baseline. At 48 weeks 31 (43%) patients continued to receive GST and 43 (62%) MTX. The median MTX dose achieved was 10 mg. Gold caused significantly more withdrawals for toxicity (43% GST v 19% MTX, p=0.0026, log rank test). Both groups experienced a significant improvement in erythrocyte sedimentation rate, C reactive protein, Ritchie Articular Index, and pain score by 24 weeks (p<0.001, Friedman test). Although a trend towards an improved Health Assessment Questionnaire (HAQ) score and global wellbeing was seen in both groups, this did not reach statistical significance. No differences in efficacy were found when the two groups were compared (Mann-Whitney).
CONCLUSION—GST and low dose MTX showed equivalent efficacy, but toxicity was more common in patients treated with GST. GST, although more toxic, remains a useful alternative for patients in whom MTX is contraindicated.



Full Text

The Full Text of this article is available as a PDF (164.0 KB).

Figure 1  .

Figure 1  

Open in a new tab

Cumulative survival on gold or methotrexate over 48 weeks.

Figure 2  .

Figure 2  

Open in a new tab

Cumulative survival before withdrawal for toxicity over 48 weeks

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón G. S., Kremer J. M., Macaluso M., Weinblatt M. E., Cannon G. W., Palmer W. R., St Clair E. W., Sundy J. S., Alexander R. W., Smith G. J. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997 Sep 1;127(5):356–364. doi: 10.7326/0003-4819-127-5-199709010-00003. [DOI] [PubMed] [Google Scholar]
  2. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  3. Beyeler C., Reichen J., Thomann S. R., Lauterburg B. H., Gerber N. J. Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol. 1997 Mar;36(3):338–344. doi: 10.1093/rheumatology/36.3.338. [DOI] [PubMed] [Google Scholar]
  4. Capell H. A., Porter D. R., Madhok R., Hunter J. A. Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? Ann Rheum Dis. 1993 Jun;52(6):423–428. doi: 10.1136/ard.52.6.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Caspi D., Tishler M., Yaron M. Association between gold induced skin rash and remission in patients with rheumatoid arthritis. Ann Rheum Dis. 1989 Sep;48(9):730–732. doi: 10.1136/ard.48.9.730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Epstein W. V. Parenteral gold therapy for rheumatoid arthritis: a treatment whose time has gone. J Rheumatol. 1989 Oct;16(10):1291–1294. [PubMed] [Google Scholar]
  7. Golden M. R., Katz R. S., Balk R. A., Golden H. E. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol. 1995 Jun;22(6):1043–1047. [PubMed] [Google Scholar]
  8. Haagsma C. J., Blom H. J., van Riel P. L., van't Hof M. A., Giesendorf B. A., van Oppenraaij-Emmerzaal D., van de Putte L. B. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis. 1999 Feb;58(2):79–84. doi: 10.1136/ard.58.2.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kalla A. A., Tooke A. F., Bhettay E., Meyers O. L. A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis. Drug Saf. 1994 Jul;11(1):21–36. doi: 10.2165/00002018-199411010-00004. [DOI] [PubMed] [Google Scholar]
  10. Katz W. A., Blodgett R. C., Jr, Pietrusko R. G. Proteinuria in gold-treated rheumatoid arthritis. Ann Intern Med. 1984 Aug;101(2):176–179. doi: 10.7326/0003-4819-101-2-176. [DOI] [PubMed] [Google Scholar]
  11. Kirwan J. R., Reeback J. S. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol. 1986 May;25(2):206–209. doi: 10.1093/rheumatology/25.2.206. [DOI] [PubMed] [Google Scholar]
  12. Kremer J. M., Alarcón G. S., Lightfoot R. W., Jr, Willkens R. F., Furst D. E., Williams H. J., Dent P. B., Weinblatt M. E. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994 Mar;37(3):316–328. doi: 10.1002/art.1780370304. [DOI] [PubMed] [Google Scholar]
  13. Kremer J. M., Alarcón G. S., Weinblatt M. E., Kaymakcian M. V., Macaluso M., Cannon G. W., Palmer W. R., Sundy J. S., St Clair E. W., Alexander R. W. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 1997 Oct;40(10):1829–1837. doi: 10.1002/art.1780401016. [DOI] [PubMed] [Google Scholar]
  14. Landewé R. B., van den Borne B. E., Breedveld F. C., Dijkmans B. A. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet. 2000 May 6;355(9215):1616–1617. doi: 10.1016/S0140-6736(00)02222-4. [DOI] [PubMed] [Google Scholar]
  15. Lewis D., Capell H. A. Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate. Clin Rheumatol. 1984 Mar;3 (Suppl 1):83–96. doi: 10.1007/BF03342626. [DOI] [PubMed] [Google Scholar]
  16. Maiden N., Capell H. A., Madhok R., Hampson R., Thomson E. A. Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients? Ann Rheum Dis. 1999 Sep;58(9):525–529. doi: 10.1136/ard.58.9.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McEntegart A., Morrison E., Capell H. A., Duncan M. R., Porter D., Madhok R., Thomson E. A. Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis. Ann Rheum Dis. 1997 Jul;56(7):410–413. doi: 10.1136/ard.56.7.410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Menninger H., Herborn G., Sander O., Blechschmidt J., Rau R. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol. 1998 Oct;37(10):1060–1068. doi: 10.1093/rheumatology/37.10.1060. [DOI] [PubMed] [Google Scholar]
  19. Morassut P., Goldstein R., Cyr M., Karsh J., McKendry R. J. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis--a randomized, double blind 26-week trial. J Rheumatol. 1989 Mar;16(3):302–306. [PubMed] [Google Scholar]
  20. Ortiz Z., Shea B., Suarez-Almazor M. E., Moher D., Wells G. A., Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol. 1998 Jan;25(1):36–43. [PubMed] [Google Scholar]
  21. Paulus H. E., Egger M. J., Ward J. R., Williams H. J. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum. 1990 Apr;33(4):477–484. doi: 10.1002/art.1780330403. [DOI] [PubMed] [Google Scholar]
  22. Pincus T., Marcum S. B., Callahan L. F. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol. 1992 Dec;19(12):1885–1894. [PubMed] [Google Scholar]
  23. Psoriasis-liver-methotrexate interactions. Arch Dermatol. 1973 Jul;108(1):36–42. [PubMed] [Google Scholar]
  24. Pullar T., Hunter J. A., Capell H. A. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) 1983 Oct 15;287(6399):1102–1104. doi: 10.1136/bmj.287.6399.1102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rau R., Herborn G., Karger T., Menninger H., Elhardt D., Schmitt J. A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J Rheumatol. 1991 Mar;18(3):328–333. [PubMed] [Google Scholar]
  26. Rau R., Herborn G., Menninger H., Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol. 1997 Mar;36(3):345–352. doi: 10.1093/rheumatology/36.3.345. [DOI] [PubMed] [Google Scholar]
  27. Ritchie D. M., Boyle J. A., McInnes J. M., Jasani M. K., Dalakos T. G., Grieveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. [PubMed] [Google Scholar]
  28. Sander O., Herborn G., Bock E., Rau R. Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate. Ann Rheum Dis. 1999 May;58(5):281–287. doi: 10.1136/ard.58.5.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sandoval D. M., Alarcón G. S., Morgan S. L. Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol. 1995 Nov;34 (Suppl 2):49–56. [PubMed] [Google Scholar]
  30. Shiroky J. B., Neville C., Esdaile J. M., Choquette D., Zummer M., Hazeltine M., Bykerk V., Kanji M., St-Pierre A., Robidoux L. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993 Jun;36(6):795–803. doi: 10.1002/art.1780360609. [DOI] [PubMed] [Google Scholar]
  31. Suarez-Almazor M. E., Fitzgerald A., Grace M., Russell A. S. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis. J Rheumatol. 1988;15(5):753–756. [PubMed] [Google Scholar]
  32. Whiting-O'Keefe Q. E., Fye K. H., Sack K. D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991 Jun;90(6):711–716. [PubMed] [Google Scholar]
  33. Wollner A., Mohle-Boetani J., Lambert R. E., Perruquet J. L., Raffin T. A., McGuire J. L. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax. 1991 Mar;46(3):205–207. doi: 10.1136/thx.46.3.205. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES